Lynparza
olaparib · PARP Inhibitor
Indications & Uses
Maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced ovarian, breast, pancreatic, and prostate cancer.
Contraindications
None.
Side Effects & Warnings
Myelodysplastic syndrome / acute myeloid leukemia, pneumonitis, nausea, fatigue, anemia, vomiting, diarrhea, thrombocytopenia, and neutropenia.
Drug & Dietary Interactions
Avoid coadministration with strong or moderate CYP3A inhibitors and inducers; reduce Lynparza dose if moderate inhibitor cannot be avoided.
Regulatory & Prescribing Information
FDA Approved NDA 208558.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.